TD 501
Alternative Names: TD-501Latest Information Update: 07 Jul 2021
At a glance
- Originator University of Ottawa
- Developer OB Pharmaceuticals
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 06 Jul 2021 TD 501 is available for licensing as of 06 Jul 2021. https://www.obpharmaceuticals.com/investors-2/ (OB Pharmaceuticals website, July 2021)
- 06 Jul 2021 Preclinical trials in Pain in Canada (unspecified route) before July 2021 (OB Pharmaceuticals website, July 2021)